Ian Estepan | Senior Vice President, Chief of Staff and Corporate Affairs |
Douglas Ingram | President and Chief Executive Officer |
Sandy Mahatme | Executive Vice President, Chief Financial Officer and Chief Business Officer |
Bo Cumbo | Executive Vice President and Chief Commercial Officer |
Gilmore O'Neill | Executive Vice President, R&D and Chief Medical Officer |
Louise Rodino-Klapac | Senior Vice President, Gene Therapy |
Ritu Baral | Cowen and Company |
Tazeen Ahmad | Bank of America Merrill Lynch |
Shawn Egan | Citi Research |
Christopher Marai | Nomura Instinet |
Bert Kinsey | RBC Capital Markets |
Alethia Young | Cantor Fitzgerald |
Maxwell Skor | Morgan Stanley |
Gena Wang | Barclays |
Debjit Chattopadhyay | H.C. Wainwright |
Anupam Rama | J.P. Morgan Securities |
Ross Weinreb | Goldman Sachs |
Vincent Chen | Bernstein |
Whitney Ijem | Guggenheim Securities, LLC |
Dae Gon Ha | SVB Leerink LLC |
Lachlan Hanbury-Brown | William Blair |
Liisa Bayko | JMP Securities |
Ladies and gentlemen, thank you for standing by and welcome to the Sarepta Therapeutics Fourth Quarter 2019 Earnings Call. At this time all participants are in a listen-only mode. After the speaker's presentation there will be a question-and-answer session. [Operator Instructions].
As a reminder, today's program may be recorded.